RenovoRx, Inc. (RNXT)
NCM · Healthcare · Biotechnology
$0.90
-0.98%
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
Market Cap
$40.5M
Shares Outstanding
45.1M
P/S (TTM)
27.2x
Exchange
NCM
Currency
USD
About RenovoRx, Inc.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 422K | 266K | 238K | 563K |
| Gross Profit | 270K | 213K | 210K | 479K |
| Operating Income | -2.7M | -3.2M | -3.5M | -3.5M |
| Net Income | -2.9M | -2.9M | -2.9M | -3.5M |
| Diluted EPS | $-0.08 | $-0.08 | $nan | $-0.09 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 43K | 1.1M |
| Gross Profit | 0.00 | 43K | 796K | |
| Operating Income | -9.9M | -11.4M | -11.0M | -12.5M |
| Net Income | -9.9M | -10.2M | -8.8M | -11.2M |
| Diluted EPS | $-1.09 | $-0.99 | $-0.40 | $-0.32 |